Top 5 Emerging Therapeutics for Crigler – Najjar Syndrome
Crigler Najjar Syndrome, also called hyperbilirubinemia, is a chronic condition characterized by high levels of unconjugated bilirubin in the blood. The disease manifests...
Coverage
- All
- Beauty
- Biotechnology
- Cannabis
- Communications
- Education
- Energy
- Entertainment
- Environment
- ETFs
- Finance
- Fitness
- Food and Beverage
- Healthcare
- Hospitality
- Insider Trading
- Investing Ideas
- Macro
- Market Insight
- Miscellaneous
- Power
- Real Estate
- Retail
- Sectors
- Security
- Startups
- Technologies
- Trending
- Uncategorized
Foamix Pharmaceuticals – Company raises nearly $64 million in financing to advance its Key Clinical Candidates in Rosacea and Acne
Foamix Pharmaceuticals (NASDAQ: FOMX), a clinical stage biotechnology company that is focused on creating solutions for the unmet needs in dermatology by developing...
Cannabix Technologies – Driving on a High? Beware of this cutting edge Marijuana Breath Analyzer!
Cannabix Technologies (OTCPK: BLOZF), a pioneer in the development of Marijuana and other drug-testing devices, announced that its scientific team has developed a...
5 Promising Companies to watch out for in the Batten Disease Therapeutic Market
Neuronal Ceroid Lipofuscinosis (NCL), or more commonly known as Batten disease, is a group of rare lysosomal storage disorders attributed to the dysfunction...
Opiant Pharmaceuticals – Partners with Sanofi to develop treatment for Acute Cannabinoid Overdose (ACO)
Opiant Pharmaceuticals, (NASDAQ: OPNT), which develops pharmacological solutions for addictions, disorders and substance abuse, announced that it has entered into an agreement with...
Puma Biotechnology – A New Drug on the Horizon for HER2 Breast Cancer Patients
Puma Biotechnology (NASDAQ: PBYI), a biopharmaceutical company focused on Oncology, announced the submission of a supplemental New Drug Application (sNDA) to the FDA,...
Positive Results from BXCL501 Trial Offers Hope to Patients with Schizophrenia related Agitation
BioXcel Therapeutics (NASDAQ: BTAI) is buoyed by the positive results from a Phase 1b clinical trial, to test the efficacy of BXCL501, its...
Avise Analytics Initiates Coverage on Bioxytran Inc.
July 23, 2019 07:00 ET | Source: Bioxytran Inc. BOSTON, MASSACHUSETTS, July 23, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage...
Tapinator Inc – One Step Ahead of the Game!
Tapinator Inc, (OTCQB: TAPM) a developer of category leading apps for mobile platforms which has built a library of more than 300 titles...
